Evidence map›Paper›PMID 39067027›Full record

ArticleBioinformatics (Oxford, England)2024

MuCoCP: a priori chemical knowledge-based multimodal contrastive learning pre-trained neural network for the prediction of cyclic peptide membrane penetration ability.

Yunxiang Yu, Mengyun Gu, Hai Guo, Yabo Deng, Danna Chen, Jianwei Wang, Caixia Wang, Xia Liu, Wenjin Yan, Jinqi Huang

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yunxiang YuSchool of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.
Mengyun GuSchool of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.
Hai GuoThe Second Hospital Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Yabo DengSchool of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.
Danna ChenSchool of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.
Jianwei WangGuangzhou First People's Hospital, South China University of Technology, Guangzhou, 510180, China.
Caixia WangGuangzhou First People's Hospital, South China University of Technology, Guangzhou, 510180, China.
Xia LiuSchool of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.
Wenjin YanSchool of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.ORCID 0000-0003-2566-7322
Jinqi HuangThe Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524000, China.

Funding

Guangdong Basic and Applied Basic Research Foundation 2022A1515220122National Natural Science Foundation of China 82270143Natural Science Foundation of Gansu Province, China 22JR5RA508Supercomputing Centre of Lanzhou University
6 · The paper itself

Abstract

motivationThere has been a burgeoning interest in cyclic peptide therapeutics due to their various outstanding advantages and strong potential for drug formation. However, it is undoubtedly costly and inefficient to use traditional wet lab methods to clarify their biological activities. Using artificial intelligence instead is a more energy-efficient and faster approach. MuCoCP aims to build a complete pre-trained model for extracting potential features of cyclic peptides, which can be fine-tuned to accurately predict cyclic peptide bioactivity on various downstream tasks. To maximize its effectiveness, we use a novel data augmentation method based on a priori chemical knowledge and multiple unsupervised training objective functions to greatly improve the information-grabbing ability of the model.

resultsTo assay the efficacy of the model, we conducted validation on the membrane-permeability of cyclic peptides which achieved an accuracy of 0.87 and R-squared of 0.503 on CycPeptMPDB using semi-supervised training and obtained an accuracy of 0.84 and R-squared of 0.384 using a model with frozen parameters on an external dataset. This result has achieved state-of-the-art, which substantiates the stability and generalization capability of MuCoCP. It means that MuCoCP can fully explore the high-dimensional information of cyclic peptides and make accurate predictions on downstream bioactivity tasks, which will serve as a guide for the future de novo design of cyclic peptide drugs and promote the development of cyclic peptide drugs. AVAILABILITY AND IMPLEMENTATION: All code used in our proposed method can be found at https://github.com/lennonyu11234/MuCoCP.

Indexed as

Neural Networks, ComputerPeptides, CyclicCell Membrane PermeabilityMachine LearningPeptides, Cyclic

Identifiers

PMID39067027
PMCPMC11315609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.